Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
ABUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $4.73
Previous CloseN/A
Volume149.14K
Average Volume (3M)1.03M
Market Cap
$670.18M
Enterprise Value$504.68M
Total Cash (Recent Filing)$83.97M
Total Debt (Recent Filing)$3.87M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
May 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding191,480,200
10 Day Avg. Volume935,963
30 Day Avg. Volume1,026,775
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)92.19
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.08
Enterprise Value/Ebitda-6.72
Forecast
1Y Price Target
$5.00Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Arbutus Biopharma News
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityManagement estimates its cash holdings to sufficiently fund its operations through the first quarter of 2028, allowing for the full funding of the upcoming imdusiran Phase 2b trial.
Legal ProceedingsA positive outcome to the Markman hearing was viewed as favorable for Arbutus.
Therapeutic DevelopmentsThe latest IM-PROVE I dataset shows that a functional cure in HBV is achievable, with imdusiran as a core component, highlighting its potential effectiveness.
Bears Say
Legal ChallengesLNP litigation process continues, with ongoing legal challenges against Pfizer/BioNTech and Moderna.
Market RisksKey risks include failed or equivocal studies, unforeseen safety or tolerability issues, meaningful delays, and the inability to sufficiently fund operations.
---
Ownership Overview
1.19% Insiders
10.63% Mutual Funds
20.25% Other Institutional Investors
57.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABUS FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $2.30 and its highest was $4.72 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Arbutus Biopharma Corporation’s market cap is $670.18M.
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is May 01, 2025 which is in 31 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on Mar 27, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.008.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -0.1.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 191,480,200 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -2.388%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Currently, no hedge funds are holding shares in ABUS
---
Arbutus Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (42.86% Upside)
$5.00 (42.86% Upside)
Blogger Sentiment
Bullish
ABUS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 515.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.65%
12-Months-Change
Fundamentals
Return on Equity
-68.76%
Trailing 12-Months
Asset Growth
-8.79%
Trailing 12-Months
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for the treatment of chronic hepatitis B virus (HBV) infection. The company's primary objective is to develop a cure for HBV by leveraging its expertise in antiviral drug development and delivery. Arbutus Biopharma's core products include proprietary HBV RNA interference (RNAi) therapeutics and small molecule antiviral agents.
---
ABUS Stock 12 Month Forecast
Average Price Target
$5.00
▲(42.86% Upside)
Technical Analysis
Gilead Sciences
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering ABUS
1 Year
1 Year Success Rate
18/34 ratings generated profit
1 Year Average Return
+6.65%
reiterated a buy rating 16 hours ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +6.65% per trade.
---